General Anesthesia Drugs Market is expected to be worth US$ 6.7 billion by 2032

The General Anesthesia Drugs Market is predicted to be worth US$ 4.7 billion by the end of 2022, and to grow at a CAGR of 3.4% to be worth US$ 6.7 billion by the end of 2032. According to a new analysis by Future Market Insights, the Propofol medication class will top the global market with a share of approximately 25.6% in 2021.

Get Full Access: https://www.futuremarketinsights.com/reports/general-anesthesia-drugs-market

“Tech advancements in drug delivery apparatus, research on patient monitoring devices, and targeted drugs for patients during and after the use of anesthesia, and reduction of side effects from modern anesthetic drugs are providing impetus to growth of the general anesthesia drugs market,” says the FMI analyst.

General Anesthesia Drugs Market – Key Takeaways

Propofol is a highly popular general anesthesia drug, aided by low risk of side effects.
Injectables remain the common general anesthesia drug delivery method, owing to superior efficacy properties.
Asia Pacific is a leading market for general anesthesia drugs, owing to rising demand for surgical intervention in chronic diseases such as diabetes.

General Anesthesia Drugs Market – Key Driving Factors

Rising cases of cardiovascular diseases is a key factor supporting the sales of general anesthesia drugs.
A rapidly ageing population with a wide range of chronic ailments generates demand for general anesthesia drugs.
Investments into research for drug delivery methods and drug formulations support market growth.

General Anesthesia Drugs Market – Key Constraints

Lack of standardization in terms of anesthesia management techniques hinders market developments.
High cost of branded anesthetics and associated medical procedures holds back market growth.

Competition Landscape

Players in the general anesthesia drugs market include but are not limited to Abbott Laboratories, AbbVie Inc., Astra Zeneca Plc, Baxter International Inc., and Fresenius SE C. KGaA. Developers are investing in investing in research for product development, and wider scope of application. For instance, sevoflurane has been found to improve outcomes of patients with sepsis.